© 2021 Aria Pharmaceuticals, Inc. | All Rights Reserved
265 Cambridge Avenue #60099
Palo Alto, CA 94306
An aria is an elaborate, sophisticated section in an opera reserved for the top performer. Just as an aria boldly advances the plot, we are dedicated to advancing bold breakthroughs in medicine. At Aria Pharmaceuticals, we believe in the work we do for patients in need. Our name exhibits the artistry and complexity that defines how we approach medicine from idea to FDA approval in a way that is scientifically sound.
Combining his experience as an entrepreneur and technologist with his passion for social responsibility, Andrew co-founded Aria Pharmaceuticals to develop life-saving medicines to help treat patients in need. Prior to co-founding Aria, Andrew held Chief Technology Officer roles at several early-stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company’s proprietary platform and as Chief Executive Officer is focused on overall company strategy, product development and fundraising. Andrew studied biomedical informatics in Stanford University’s SCPD graduate program and holds Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.
One of Aria Pharmaceuticals’ first employees, Aaron has helped build Aria’s drug discovery platform and leads the Discovery Science team’s efforts to discover potential treatments across a wide range of diseases. Aaron earned his PhD in Genetics from Stanford University. Prior to his time at Stanford, Aaron was a Fulbright Scholar and received his Bachelor of Science in Biology from the University of Richmond.
CEO & Managing Partner
Softbank Ventures Asia
Chief Financial Officer
Andrew M. Radin
Aria pharmaceuticals Co-founder